Cancer clinical trials in the region Grand Est

279 currently recruiting clinical trials
Region Grand Est

Phase 3 Breast cancer #NCT05633654
Required HER2 statuses
HER2 Negative
Required HR statuses
HR Negative
Required disease stage
Localized Locally Advanced
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at localized stage
Surgery Chemotherapy Radiotherapy
Required previous treatments at advanced or metastatic stage
Surgery Chemotherapy Radiotherapy
Excluded genetic anomalies
BRCA 1/2
Excluded previous treatments at localized stage
Systemic Treatment-Naive Immunotherapy Antibody Drug Conjugates (ADC)
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive Immunotherapy Antibody Drug Conjugates (ADC)
15 recruiting sites
Gilead Sciences
Phase 3 Lung cancer #NCT06801834 #2024-515884-69-00
Required histologic types
SCLC (Small Cell Lung Cancer)
Required disease stage
Locally Advanced Metastatic
Required number of previous lines of therapy for current stage of disease
1
Required previous treatments at advanced or metastatic stage
Chemotherapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
12 recruiting sites
Gilead Sciences
Phase 3 Lung cancer #NCT06422143 #2023-510128-66-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required histologic sub types
Squamous NSCLC
Required disease stage
Metastatic
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Excluded previous treatments at localized stage
Immunotherapy Antibody Drug Conjugates (ADC)
Excluded previous treatments at advanced or metastatic stage
Immunotherapy Antibody Drug Conjugates (ADC)
5 recruiting sites
Merck Sharp & Dohme LLC
Phase 3 Head and neck cancer #NCT04892173
Required histologic types
Oral cavity Oropharynx Hypopharynx Larynx
Required histologic sub types
Squamous cell carcinoma
Required disease stage
Locally Advanced
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Excluded previous treatments at advanced or metastatic stage
Surgery Chemotherapy Radiotherapy Radiochemotherapy
15 recruiting sites
Johnson & Johnson Enterprise Innovation Inc.
Phase 3 Acute leukemia #NCT07007312 #2025-521314-25-00
Required histologic types
Acute myeloid leukemia (AML)
Required genetic anomalies
NPM1
Required number of previous lines of therapy
None
Required previous treatments
Systemic Treatment-Naive
Excluded genetic anomalies
BCR-ABL
12 recruiting sites
Kura Oncologie, Inc.
Phase 3 Acute leukemia #NCT07007312 #2025-521314-25-00
Required histologic types
Acute myeloid leukemia (AML)
Required genetic anomalies
KMT2A NPM1
Required number of previous lines of therapy
None
Required previous treatments
Systemic Treatment-Naive
Excluded genetic anomalies
BCR-ABL
12 recruiting sites
Kura Oncologie, Inc.
Phase 3 Penile cancer and germ cell tumors #NCT05874063 #2022-502426-41-00
Required histologic types
Germ cell tumor
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at localized stage
Systemic Treatment-Naive
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Required IGCCCG prognostic scores
Good prognosis Intermediate prognosis
18 recruiting sites
Gustave Roussy, Campus du cancer, Grand Paris
Phase 3 Head and neck cancer #NCT06525220 #2023-510323-30-00
Required histologic types
Oral cavity Oropharynx Hypopharynx Larynx
Required histologic sub types
Squamous cell carcinoma
Required disease stage
Locally Advanced Metastatic
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Required CPS scores
CPS Positive (1 <= X < 20) CPS Positive (X >= 20)
14 recruiting sites
Merus
Phase 3 Breast cancer #NCT07237256 #2025-520979-13-00
Required HER2 statuses
HER2 Negative
Required HR statuses
HR Positive
Required disease stage
Localized
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at localized stage
Systemic Treatment-Naive Surgery
Excluded previous treatments at localized stage
Chemotherapy Targeted therapy
17 recruiting sites
UNICANCER
Phase 3 Lymphoma #NCT06717347 #2024-515566-13-00
Required histologic types
B cell lymphoma
Required histologic sub types
Large B cell lymphoma
Required central nervous system lesions
None Treated / Controled
Required number of previous lines of therapy
None
Required previous treatments
Systemic Treatment-Naive
14 recruiting sites
Merck Sharp & Dohme LLC